Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

The question of which pharma giant will acquire rare disease-focused Acceleron Pharma appears to be over. Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.